15 not yet recruiting, 5 recruiting, 3 unknown, 1 completed. 13 Phase 2, 5 Phase 1, 4 Not applicable, 1 Phase 3.
Follow HSCT: new trials by email Literature Review of HSCT trials Research Report on HSCT
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Unraveling Dynamics and Clinical Impact of Tregs in Allogeneic HSCT With PTCy HSCT | Not yet recruiting | Ciceri Fabio | 70 | 2026-11-01 | 2026-10-20 | |
| Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. Sonrotoclax, cladribine, and standard-dose cytarabine - AML (Acute Myelogenous Leukemia, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2026-09-01 | 2026-08-11 |
| Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients Tezepelumab - Bronchiolitis Obliterans Syndrome (BOS), HSCT | Phase 2 | Recruiting | Hopital Foch | 36 | 2026-06-24 | 2026-08-18 |
| HBV Reactivation Prediction Model in Allo-HSCT No Intervention: Observational Cohort - HBV Reactivation, HSCT | Not yet recruiting | Xiao Hui Zhang | 300 | 2026-06-20 | 2026-06-12 | |
| Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day - GVHD - Graft-Versus-Host Disease, HSCT | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 180 | 2026-06-01 | 2026-05-12 |
| The Efficacy and Safety of Stereotactic Radiotherapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignance Patients With Extramedullary Infiltrating Stereotactic body radiotherapy (SBRT) - HSCT, Hematologic Cancer | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-04-14 | 2026-03-06 |
| Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis Gecacitinib (also known as Jaktinib) - Myelofibrosis (MF), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 39 | 2026-03-16 | 2026-03-13 |
| Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). Gecacitinib - cGVHD, HSCT | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 33 | 2026-03-16 | 2026-03-17 |
| The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT Luspatercept - HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-04 |
| Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL Olverembatinib+INO - HSCT, Ph+ ALL | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-03-14 | 2026-03-02 |
| Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function HSCT, Pediatric Cancer | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2026-02-15 | 2026-02-20 | |
| Zuberitamab for EBV Infection Post-Allo-HSCT Zuberitamab - HSCT, EBV Infection | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-01-14 | 2025-12-03 |
| Study of Treosulfan-Based Conditioning for HSCT in Nijmegen Breakage Syndrome Treosulfan (Treo) - HSCT, Nijmegen Breakage Syndrome | Phase 2 | Not yet recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 24 | 2025-12-30 | 2026-01-05 |
| Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Cardiotoxicity, DPP3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2025-12-25 | 2026-09-25 | |
| Modified Conditioning Regimen for CML-BP Enrolled patients with blast-phase chronic myeloid leukemia received a reduced-toxicity conditioning regimen containing thiotepa, melphalan, and fludarabine prior to undergoing allogeneic hematopoie - CML,Blast Phase, HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 40 | 2025-12-15 | 2025-12-02 |
| Romiplostim N01 for Platelet Recovery After Haploidentical HSCT Romiplostim N01, Standard Supportive Care - Acute Myeloid Leukemia, MDS (Myelodysplastic Syndrome) | Phase 1 | Recruiting | First Affiliated Hospital of Zhejiang University | 130 | 2025-06-01 | 2026-01-28 |
| Reduced-dose Conditioning Regimen Containing TBI in HSCT Treating Elderly Patients With Aplastic Anemia reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia - Aplastic Anaemia, HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-31 | 2025-01-10 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL Olverembatinib is used to prevent recurrence or preemptive treatment after transplantation. - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), HSCT | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2024-11-01 | 2024-10-26 |
| Comparison of Intralipid With SMOF Lipid Following HSCT SMOF lipid, INTRALIPIDS - Leukemia, HSCT | Not applicable | Recruiting | Shahid Beheshti University | 50 | 2024-10-12 | 2024-10-16 |
| Assessing Pulmonary Changes in HSCT Hyperpolarized 129 Xenon - HSCT, Respiratory | Phase 1 / Phase 2 | Recruiting | Children's Hospital Medical Center, Cincinnati | 550 | 2024-07-24 | 2026-09-16 |
Showing 20 of 25. Sign in to see all of them.
Leukemia (2) · Leukemia, Myeloid, Acute (2) · Acute Coronary Syndrome (1) · Anemia, Aplastic (1) · Anemia, Refractory, with Excess of Blasts (1) · Arrhythmias, Cardiac (1) · Bronchial Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiotoxicity (1) · Cognition Disorders (1) · Cytomegalovirus Infections (1) · Epstein-Barr Virus Infections (1) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Hypertension, Pulmonary (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Neoplasms (5) · Neoplasms by Histologic Type (4) · Bone Marrow Diseases (3) · Immune System Diseases (3) · Anemia (2) · Cardiovascular Diseases (2) · DNA Virus Infections (2) · Herpesviridae Infections (2) · Infections (2) · Leukemia (2) · Leukemia, Myeloid (2) · Lung Diseases (2) · Respiratory Tract Diseases (2)
Cladribine (1) · Cyclophosphamide (1) · Cytarabine (1) · Educational Status (1) · Melphalan (1) · Radiosurgery (1) · luspatercept (1) · tezepelumab (1) · treosulfan (1)
Institute of Hematology & Blood Diseases Hospital, China (10) · Assistance Publique - Hôpitaux de Paris (2) · Children's Hospital Medical Center, Cincinnati (2) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (2) · Ciceri Fabio (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dartmouth-Hitchcock Medical Center (1) · First Affiliated Hospital of Zhejiang University (1) · Hopital Foch (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Shahid Beheshti University (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Xiao Hui Zhang (1)
France (3) · United States (3) · China (2) · Denmark (1) · Iran (1) · Italy (1) · Russia (1) · Spain (1)
Laura Walkup, PhD (1) · Michael Maschan, PhD (1) · Xianmin Song, M.D (1) · Zahra Vahdat Shariatpanahi, Professor (1)